roledumab
mAbexperimental
Roledumab is a monoclonal antibody. It binds to RHD, the Rhesus factor antigen. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2009 (NCT00952575)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Blood group Rh(D) polypeptideINHIBITOR
RHD inhibitor
Fully human IgG1 targeted against the human RhD antigen on RhD-positive circulating RhD-reactive B cells (RBCs).Clears of antibody-coated RhD RBCs.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRoledumab ↗
- ChEMBLCHEMBL1743065 ↗
Also known as
- lfb-r593
- roledumab
- roledumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02287896 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2014 | Centre Hospitalier Princesse Grace, Laboratoire français de Fractionnement et de Biotechnologies |
| NCT00952575 | Phase 2 | Aug 1, 2009 | Laboratoire français de Fractionnement et de Biotechnologies, Parexel |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Laboratoire français de Fractionnement et de Biotechnologies | For profit | 2 | 2 | 2 | 2009 |
| Centre Hospitalier Princesse Grace | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Parexel | For profit | 1 | 0 | 1 | 2009 |
3 organizations
Page 1 / 1